Entering text into the input field will update the search result below

NeoStem to drive shareholder value, says Rodman & Renshaw

May 26, 2011 3:29 PM ETLSTA
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Short Only

Seeking Alpha Analyst Since 2009

Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world. The group also operates hugely successful “investor forums” where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts. Ian Mclelland founded Proactiveinvestors in 2006 as a way to channel his own views on companies small and mid-cap public companies. What started as a hobby quickly turned into a full time job as the website's readership exploded. One2One forums were added later in 2006, and within two years the company had expanded its operations into Canada and Australia. In 2009 the company expanded into Germany and finally into the US in 2010. Proactiveinvestors is now one of the fastest growing global financial media organizations in the world receiving more than one million visitors per month, with investor forums held across the globe on a regular basis.

NeoStem (AMEX:NBS) said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company's market outperform rating, based on "multiple milestones to drive shareholder value".

Since starting out as a provider of adult stem cell collection and storage services, New York-based NeoStem has since branched out into cell therapeutics, focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US. Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

According to Rodman, the Progenior acquisition unlocks significant upside potential. In the first quarter NeoStem reported pro forma revenues of $1.5 million from its stem cell-related business, $1.4 million of which was attributable to Progenitor.

As a result of the acquisition, NeoStem can also now develop stem cell therapies in-house, placing it in a solid position for future growth in the field. Revenues from Progenitor are estimated to reach $9 million by 2013, said Rodman.

But aside from this, the company is benefiting significantly from its Chinese pharmaceuticals business, reporting pharmaceutical revenues of $18.1 million in the first quarter, a 15% growth over the year-ago period. NeoStem owns a 51% stake in Chinese generic pharmaceutical company Suzhou Erye.

In addition to the 160 marketed products focused on antibiotics, Suzhou also has a number of drugs in the pipeline, with plans to launch omeprazole, a widely used drug for acid-induced inflammation, in the third quarter, as well as an another product in the following quarter.

With this growing pipeline to fuel future growth, Rodman & Renshaw project a revenue growth rate of 20% during 2011-2013, with the potential to reach $119 million in pharmaceutical sales by 2013.

NeoStem has also just formed a third lucrative partnership with a hospital in China for its stem cell therapies. In each case, the company has built an in-hospital laboratory, with the rights to conduct an autologous adult stem cell-based treatment for orthopedic indications.

Going forward, NeoStem anticipates securing a total of six collaborations with hospitals by year end, and could generate revenue of $2 million from this business by 2013.

Rodman & Renshaw noted that NeoStem, with $9.4 million in cash and equivalents at first quarter-end, has enough to sustain itself through the fourth quarter. The company also has an additional $18 million equity line of credit.

Based on all these developments, the equity research firm gave the company a 12 month price target of $3 per share, up from its current trading price of $1.59.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.